October 5-7 | Arizona Biltmore

20 Jul March Biosciences

Posted at 14:45h in by Brittany Miller

Leah DiMascio, Ph.D., Chief Operating Officer

Oct. 7 | 10:00am | FLW Ballroom F

Houston, Texas

(Private)

March Biosciences is dedicated to addressing challenging cancers unresponsive to current immunotherapies. Its lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 2 clinical development for patients with relapsed / refractory T-cell lymphoma. The company has raised over $52 million to date, inclusive of venture financing, support from the Cancer Prevention & Research Institute of Texas (CPRIT), and the NIH SBIR program.

www.march.bio

About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 110+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,500 attendees – over 30% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 5-7, 2026
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions